Limon-De La Rosa Nathaly, Cervantes-Alvarez Eduardo, Navarro-Alvarez Nalu
Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; El Plan de Estudios Combinados en Medecina, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Clin Gastroenterol Hepatol. 2022 Jan;20(1):239-241.e3. doi: 10.1016/j.cgh.2021.08.053. Epub 2021 Sep 2.
It has been recently reported that patients with cirrhosis have significantly higher mortality following severe acute respiratory syndrome coronavrisu 2 (SARS-CoV-2) infection compared with those without. Specifically, it was demonstrated that mortality was greater in those with advanced cirrhosis (Child-Pugh B and C), and that from cirrhotic patients experiencing SARS-CoV-2 infection, close to half suffer acute decompensation including acute-on-chronic liver failure (ACLF). Unfortunately, the presence of hepatic decompensation at baseline has been shown to be an independent predictor of all-cause mortality in patients with coronavirus disease 2019 (COVID-19). Patients with decompensated cirrhosis contracting COVID-19 have a poor outcome, with an overall reported mortality of over 30%..
最近有报道称，与非肝硬化患者相比，肝硬化患者感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）后的死亡率显著更高。具体而言，研究表明，晚期肝硬化（Child-Pugh B级和C级）患者的死亡率更高，并且在感染SARS-CoV-2的肝硬化患者中，近一半会出现急性失代偿，包括慢加急性肝衰竭（ACLF）。不幸的是，基线时存在肝失代偿已被证明是2019冠状病毒病（COVID-19）患者全因死亡率的独立预测因素。失代偿期肝硬化患者感染COVID-19的预后较差，总体报道死亡率超过30%。
